Elisabetta Fenocchio

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jiajia Tang · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
2. Yaru Zhao · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
3. Da Fu · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
4. Berina Šabanović · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
5. Quan Zheng · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
6. Chenlei Wen · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
7. Baiyong Shen · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
8. Qi Wang · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
9. Christopher Heeschen · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
10. Ke Jiang · 1 shared paper, 2024 · strength 0.15
    • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
11. Claudio De Angelis · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
12. Claudia Curcio · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
13. Silvia Brugiapaglia · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
14. Alessandro Ferrero · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
15. Serena Langella · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
16. Rosella Spadi · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
17. Francesco Novelli · 1 shared paper, 2023 · strength 0.14
    • Paper Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prog… DOI 10.1007/s10238-023-01236-5↗
18. Francesco Leone · 1 shared paper, 2019 · strength 0.10
    • Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
19. Pasquale Lombardi · 1 shared paper, 2019 · strength 0.10
    • Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗
20. Massimo Aglietta · 1 shared paper, 2019 · strength 0.10
    • Paper Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? DOI 10.3390/cancers11101547↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.